INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 426m ago
HOUSE PTR25m ago
SEC 13F25m ago
ROBINHOOD CHAIN25m ago
SEC FORM 4/Open-market saleVerified dataRule 10b5-1 plan

Malabre Richard C sold AKBA

SVP, Chief Accounting Officer · Akebia Therapeutics, Inc. · Common Stock

Side
SELL
Value
$50K
Shares
36.1K
Price
$1.39
Executed
Feb 2, 2026
Disclosed
Feb 4, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Feb 2 executedFeb 4, 2026 disclosed

AKBA · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
17/ 100 · ROUTINE
Methodology →
  • Transaction type+6 / 20

    Open-market sale

  • Relative size+8 / 25

    $50K reported value · 10.4% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering+5 / 15

    1 other actor traded the same direction within 14 days

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · AKBA

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    15
    FR
    Frieson RonDirector
    AKBAAkebia Therapeutics, Inc.
    Grant or award
    		A—
    53.6K sh
    		Jun 17, 2026Jun 22, 2026
    traded Jun 17, 2026
    		+5dSEC FORM 4

    Evidence

    23
    FR
    Frieson RonDirector
    AKBAAkebia Therapeutics, Inc.
    Grant or award
    		A—
    35.7K sh
    		Jun 17, 2026Jun 22, 2026
    traded Jun 17, 2026
    		+5dSEC FORM 4

    Evidence

    10
    RM
    Rucci Carolyn M.SVP, Chief Legal Officer
    AKBAAkebia Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$35K
    25.4K sh
    		Feb 2, 2026Feb 4, 2026
    traded Feb 2, 2026
    		+2dSEC FORM 4

    Evidence

    10
    RM
    Rucci Carolyn M.SVP, Chief Legal Officer
    AKBAAkebia Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$38K
    27.5K sh
    		Feb 2, 2026Feb 4, 2026
    traded Feb 2, 2026
    		+2dSEC FORM 4

    Evidence

    10
    RM
    Rucci Carolyn M.SVP, Chief Legal Officer
    AKBAAkebia Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$23K
    16.8K sh
    		Feb 2, 2026Feb 4, 2026
    traded Feb 2, 2026
    		+2dSEC FORM 4

    Evidence

    10
    MC
    Malabre Richard CSVP, Chief Accounting Officer
    AKBAAkebia Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$19K
    13.4K sh
    		Feb 2, 2026Feb 4, 2026
    traded Feb 2, 2026
    		+2dSEC FORM 4

    Evidence

    17
    RM
    Rucci Carolyn M.SVP, Chief Legal Officer
    AKBAAkebia Therapeutics, Inc.
    Grant or award
    		A—
    190.0K sh
    		Jan 30, 2026Feb 3, 2026
    traded Jan 30, 2026
    		+4dSEC FORM 4

    Evidence

    17
    MC
    Malabre Richard CSVP, Chief Accounting Officer
    AKBAAkebia Therapeutics, Inc.
    Grant or award
    		A—
    79.0K sh
    		Jan 30, 2026Feb 3, 2026
    traded Jan 30, 2026
    		+4dSEC FORM 4

    Evidence

    9
    RM
    Rucci Carolyn M.SVP, Chief Legal Officer
    AKBAAkebia Therapeutics, Inc.
    Grant or award
    		A—
    270.0K sh
    		Jan 30, 2026Feb 3, 2026
    traded Jan 30, 2026
    		+4dSEC FORM 4

    Evidence

    9
    MC
    Malabre Richard CSVP, Chief Accounting Officer
    AKBAAkebia Therapeutics, Inc.
    Grant or award
    		A—
    119.0K sh
    		Jan 30, 2026Feb 3, 2026
    traded Jan 30, 2026
    		+4dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002007730-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Feb 2, 2026
    Published
    Feb 4, 2026
    Ingested by INSIDER
    Nov 5, 04:19 UTC
    Last re-read
    Nov 5, 04:19 UTC

    Extracted facts

    Filer
    Malabre Richard C
    Role
    SVP, Chief Accounting Officer
    Transaction
    Open-market saleAs filed: “S”
    Asset
    Akebia Therapeutics, Inc.
    Ticker
    AKBA
    Shares
    36.1K
    Price per share
    $1.39
    Value
    $50,237
    Execution date (reported)
    Feb 2, 2026
    Owned after transaction
    312.8K shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    2

    Calculation

    Value = shares × reported price per share

    • Shares: 36.1K
    • Price: $1.39

    = $50,237

    What this establishes

    Malabre Richard C filed this Form 4 reporting a open-market sale of AKBA on Feb 2, 2026. It became public on Feb 4, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    SVP, Chief Accounting Officer
    Malabre Richard Ccik:0002007730
    Issuer
    Akebia Therapeutics, Inc.cik:0001517022

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.